针对PKC-Gli轴:布里奥斯塔丁1作为刺途径抑制剂
UyenPhuong Tran1, Kelvin L Billingsley2
1Department of Chemistry and Biochemistry, California State University Fullerton, Fullerton, California 92831, United States.
Journal of natural products
|October 22, 2025
概括
布里奥斯塔丁1通过抑制Gli活动,有效地抑制了Smo下游的Hh信号传递. 这种天然化合物在克服Hh驱动癌症的抵抗方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 异常的刺 (Hh) 信号涉及到许多癌症的发病.
- 目前针对Smo的疗法经常面临药物耐药性和疾病复发的挑战.
- 迫切需要新的治疗策略来克服Hh驱动的恶性瘤的抗性.
研究的目的:
- 调查自然产品布里奥斯塔丁1的潜力,以抑制Hh信号传递.
- 为了确定布里奥斯塔丁1能否克服对Smo向疗法的耐药性.
- 在Hh驱动的癌症模型中评估布里奥斯塔丁1的疗效和选择性.
主要方法:
- 评估了布里奥斯塔丁1对Gli转录活性的影响.
- 量化了布里奥斯坦丁1治疗后关键Hh通路组件的表达.
- 评估了布里奥斯塔丁1对癌细胞活力的影响,与健康的纤维细胞相比.
主要成果:
- 布里奥斯塔丁1显示强烈抑制了Gli转录活性.
- 观察到Hh通路组件表达的显著,时间和剂量依赖的减少.
- 布里奥斯塔丁1在Hh驱动的癌细胞中选择性地降低了活力,节省了正常的纤维细胞.
结论:
- 布里奥斯塔丁1有效地抑制了SMO的下游的HH信号传输.
- 布里奥斯塔丁1表现出抗癌活性和选择性,提供了对抗Hh驱动癌症的潜在策略.
- 布里奥斯塔丁1代表了一个有前途的治疗候选人,可以克服Hh驱动的侵袭性疾病的抗性.
更多相关视频
07:16Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
20.6K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.5K
相关概念视频
Hedgehog Signaling Pathway
9.8K
The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
9.8K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
The JAK-STAT Signaling Pathway
12.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.0K
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
